Shares of ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.71 and traded as low as $1.70. ESSA Pharma shares last traded at $1.73, with a volume of 67,146 shares.
ESSA Pharma Price Performance
The company has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $1.68. The stock has a market cap of $76.79 million, a PE ratio of -2.75 and a beta of 1.58.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. On average, equities analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Tang Capital Management LLC purchased a new stake in shares of ESSA Pharma during the 4th quarter worth approximately $7,697,000. BML Capital Management LLC acquired a new position in ESSA Pharma during the fourth quarter worth $7,557,000. Altium Capital Management LLC purchased a new stake in ESSA Pharma during the fourth quarter worth $2,556,000. Bank of America Corp DE grew its holdings in ESSA Pharma by 10,153,775.0% in the fourth quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock valued at $1,454,000 after purchasing an additional 812,302 shares during the last quarter. Finally, Aldebaran Capital LLC grew its holdings in ESSA Pharma by 43.2% in the first quarter. Aldebaran Capital LLC now owns 569,294 shares of the company's stock valued at $899,000 after purchasing an additional 171,771 shares during the last quarter. 75.12% of the stock is owned by hedge funds and other institutional investors.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Read More
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
